Braster Valuation
Is 7UD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 7UD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 7UD (€0.09) is trading below our estimate of fair value (€3.22)
Significantly Below Fair Value: 7UD is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 7UD?
Key metric: As 7UD barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 7UD's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | -zł5.09m |
| Market Cap | zł17.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 22.7x |
| Enterprise Value/EBITDA | -24.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 7UD's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
MF6 MagForce | 0.1x | 149.0% | €3.6m |
AUG Audientes | 3.9x | n/a | €6.9m |
GME Geratherm Medical | 0.7x | 89.5% | €14.6m |
AAQ1 aap Implantate | 1.5x | n/a | €22.2m |
7UD Braster | n/a | n/a | €17.0m |
Price-To-Book vs Peers: Insufficient data to calculate 7UD's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does 7UD's PB Ratio compare vs other companies in the DE Medical Equipment Industry?
| 2 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate 7UD's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is 7UD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 7UD's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.12
7D
-3.1%
1Y
5.2%
Shandong Weigao Group Medical Polymer
HK$20.6b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-13.2%
1Y
-37.9%
LNA Santé
€243.4m
Engages in the management and operation of health establishments.
2N3
€23.45
7D
-5.6%
1Y
16.1%